Discover a world of educational opportunities to support your lifelong learning
Practice Experience Program is a self-directed education program designed to support non vocationally registered doctors on their pathway to RACGP Fellowship
RACGP offer courses and events to further develop the knowledge you need to develop your GP career
2022 RACGP curriculum and syllabus
for Australian general practice
The Abuse and violence: working with our patients in general practice provides the best-available current evidence for GPs
Stay up-to-date with the latest information and resources on the COVID-19 vaccine rollout.
Download the Standards for general practice (5th edition) - a benchmark for quality care and risk management in Australian general practices
Coronavirus (COVID-19) resources for general practitioners
Advice and guidelines for GPs and practice teams to help protect general practice information systems
Video consultations can provide convenient and accessible healthcare delivery
Read all of the RACGP reports and submissions on various healthcare topics
Read all of the RACGP position statements on various healthcare topics
Join our RACGP Facebook groups
Home-care guidelines for patients with COVID-19
Refer to the latest National COVID-19 Clinical Evidence Taskforce living guidelines and clinical flowcharts for the management of adults with mild and moderate–severe COVID-19.
Determine the patient’s eligibility for oral antiviral COVID-19 treatments (Lagevrio (molnupiravir) and Paxlovid (nirmatrelvir with ritonavir)) or other treatments that are recommended by the National COVID-19 Clinical Evidence Taskforce for patients who have mild-moderate illness and who do not require oxygen.
The initiation of these medicines is time-critical. Lagevrio (molnupiravir) and Paxlovid (nirmatrelvir with ritonavir) must be commenced within five days of symptom onset, so early assessment and intervention are vital. This could be done in collaboration with the commissioned triaging health service, hospital or infectious disease specialists.
Adults who have mild to moderate COVID-19 confirmed by a PCR or medically verified RAT and who can start treatment within five days of symptom onset, can be prescribed PBS-subsidised Lagevrio (molnupiravir) or Paxlovid (nirmatrelvir with ritonavir) if (excluding contraindications):
More information on Lagevrio (molnupiravir) and Paxlovid (nirmatrelvir with ritonavir) is available on the RACGP website.
*in people aged 70 years of age and above treatment can be initiated as soon as possible after diagnosis is confirmed even if the patient is asymptomatic.